Kilambi News
Sunday, November 22, 2026

Archive

Every story, newest first.

Friday, October 30, 2026

Life Sciences

Merck Keytruda sales beat as Qlex injection reaches $830 million

Merck reported third quarter sales up 5 percent to $18.1 billion on October 29, with combined Keytruda and Keytruda Qlex sales up 6 percent to $8.6 billion, including $830 million from the Qlex injection in its strongest quarter since launch.

Life Sciences

Life sciences also notable: Genmab record, UK budget pledges

Genmab's market value rose by more than $7 billion to pass $35 billion after its Phase 3 win, and the UK Autumn Budget carried more than £1 billion of life sciences investment pledges, leading the smaller life sciences items for October 30.

Life Sciences

Labor Department finalizes sweeping PBM disclosure rule for employers

The Department of Labor finalized a rule on October 29 requiring pharmacy benefit managers to disclose their compensation, including rebates and spread pricing, to large self insured employer plans, with requirements applying to plan years starting July 1, 2027.

Life Sciences

Iovance biomarker subgroup lifts lifileucel lung response to 59.1 percent

Iovance reported on October 29 that lifileucel produced a 24.6 percent response rate in 69 patients with previously treated non squamous lung cancer, rising to 59.1 percent in a retrospectively defined biomarker subgroup of 22 patients, and will test that subgroup prospectively in a new registrational intent study from November.

Life Sciences

Incyte raises sales guidance as business beyond Jakafi grows

Incyte reported third quarter total revenue up 14 percent to $1.56 billion on October 29 and raised full year total net sales guidance to $5.210 billion to $5.300 billion, as Opzelura sales rose 36 percent to $255 million.

Life Sciences

Gilead raises product sales guidance on 18 percent HIV growth

Gilead reported third quarter product sales up 13 percent to $8.3 billion on October 29 and raised full year product sales guidance to $31.0 billion to $31.3 billion, from $30.1 billion to $30.4 billion, as HIV sales rose 18 percent.

Life Sciences

Dren Bio closes $350 million financing to launch dibotatug itself

Dren Bio announced on October 29 the closing of an oversubscribed $350 million private financing, co led by Juvia Group and Lightspeed Venture Partners, to fund late stage development, regulatory submission and a planned commercial launch of its CD94 antibody dibotatug.

Life Sciences

Bristol Myers raises revenue guidance as growth portfolio rises 12 percent

Bristol Myers Squibb reported third quarter revenues up 7 percent to $13.1 billion on October 29 and raised full year 2026 revenue guidance to $49.75 billion to $50.25 billion, as growth portfolio revenues rose 12 percent to $7.7 billion.

Politics

Aliyev skips Ankara summit as Turkiye Azerbaijan rift shows

Azerbaijan's President Ilham Aliyev will not attend Friday's Organization of Turkic States summit in Ankara, sending his foreign minister instead, in an absence widely read as a signal of strain with Turkiye over its criticism of Azerbaijan's school headscarf restrictions.

Politics

Albanian opposition sets off flares in parliament amid protests

Opposition lawmakers set off flares and smoke bombs in Albania's parliament on Thursday and blocked a central bank bill vote, after weeks of student led protests demanding Prime Minister Edi Rama's resignation.